NanoDx, Inc. is a privately-held, U.S. based, medical device company developing rapid point-of-care and in-vitro diagnostic products on its proprietary nanowire biosensor platform. The NanoDx™ System provides for direct measurement of blood and saliva analytes normally in less than 2 minutes from either a drop of whole blood or a small sample of saliva. In partnership with IBM and SkyWater Technologies, a low-cost, high-volume, licensed CMOS process has been integrated into NanoDx’s highly-advanced proprietary platform. The System consists of a single-use, disposable test cartridge and an analyzer. The company is focused on two near-term indications: traumatic brain injury (TBI) and Covid-19. The NanoDx™ System offers compelling competitive advantages based on its ultra-sensitivity and accuracy, speed, value, and ease-of-use. Additional potential diseases and conditions include stroke, sepsis, influenza and inflammatory diseases. FDA has not yet reviewed this product and it has not been cleared. Currently for research use only.